| Overview |
| bs-9547R-RBITC |
| PGGT1A Polyclonal Antibody, RBITC Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PGGT1A/FNTA |
| 301-379/379 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2339 |
| CAAX farnesyltransferase alpha subunit; Farnesyl protein transferase alpha subunit; Farnesyltransferase CAAX box alpha; Farnesyltransferase, CAAX box, alpha; FPTA; FTase alpha; GGTase I alpha; PGGT1A; Protein farnesyltransferase/geranylgeranyltransferase type I alpha subunit; Protein prenyltransferase alpha subunit repeat containing 2; PTAR2; Ras proteins prenyltransferase alpha; Ras proteins prenyltransferase subunit alpha; Type I protein geranyl geranyltransferase alpha subunit; FNTA_HUMAN. |
| FNTA, also known as CAAX farnesyltransferase (FTase), attaches a farnesyl group from farnesyl pyrophosphate to cysteine residues at the fourth position from the C terminus of proteins that end in the so-called CAAX box, where C is cysteine, A is usually but not always an aliphatic amino acid, and X is typically methionine or serine. This type of posttranslational modification provides a mechanism for membrane localization of proteins that lack a transmembrane domain. This enzyme has the remarkable property of farnesylating peptides as short as four residues in length that conform to the CAAX consensus sequence. FNTA is also a specific cytoplasmic interactor of the transforming growth factor-beta and activin type I receptors. It is likely to be a key component of the signaling pathway which involves p21ras, an important substrate for farnesyltransferase. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz